Full data from the Phase 3 CORE-TIMI 72a and CORE2-TIMI 72b studies of olezarsen in a total of 1,061 patients with severe hypertriglyceridaemia (sHTG) confirm the promising top line findings announced earlier this year. There was a significant placebo-adjusted mean reduction in fasting TG levels of up to 72% at six months (p<0.001), remaining stable at 12 months, and an 85% reduction in acute pancreatitis events at 12 months (p<0.001).1,2
The results, published simultaneously in the New England Journal of Medicine, also showed that, among patients with TG > 800 mg/dL at baseline, 89.4% of those on olezarsen 50 mg had TG levels below that level at 12 months, as did 88.0% of those on olezarsen 80 mg. This compared with 44.4% of those on placebo (p<0.001 for each comparison). Similarly, among those with TG levels > 500 mg/dL at baseline, 85.8% of those on olezarsen 50 mg and 85.7% of those on olezarsen 80 mg had TG levels below that level at 12 months, compared to 35.3% receiving placebo (p<0.001 for each comparison).
